Abstract
No public abstract is available from the verified source records.
Open public full textRights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureLinde Dekker, Coco C. H. de Koning, A. Laura Nijstad, Kim C. M. van der Elst, Rick Admiraal, A. Birgitta Versluijs, Jaap Jan Boelens, Alwin D. R. Huitema, Caroline A. Lindemans
Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Long-term outcomes after treatment with clofarabine ± fludarabine with once-daily intravenous busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and myelodysplastic syndrome
10.1016/j.bbmt.2016.06.023 · 2016
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling
10.1016/j.bcp.2010.09.027 · 2011
Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines
10.3109/10428194.2011.634043 · 2012
Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study
10.1200/jco.20.02529 · 2021
The impact of severe late-effects after 12 Gy fractionated total body irradiation and allogeneic stem cell transplantation for childhood leukemia (1988-2010)
10.1080/08880018.2019.1591549 · 2019
Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen
10.1182/bloodadvances.2021005224 · 2022
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis
10.1016/s2352-3026(16)30114-4 · 2016
Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
10.1038/bmt.2016.322 · 2017
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes
10.1182/bloodadvances.2018029421 · 2019
Pharmacokinetics and model-based dosing to optimize fludarabine therapy in pediatric hematopoietic cell transplant recipients
10.1016/j.bbmt.2017.06.021 · 2017
Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation
10.1182/blood-2016-06-721936 · 2016
Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial
10.1016/s2352-3026(21)00375-6 · 2022
Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in pediatric patients
10.1111/bcp.14738 · 2021
Population pharmacokinetics of clofarabine as part of pretransplantation conditioning in pediatric subjects before hematopoietic cell transplantation
10.1016/j.bbmt.2019.04.017 · 2019
Population pharmacokinetic modeling of Thymoglobulin® in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing
10.1007/s40262-014-0214-6 · 2015
Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis
10.1016/s2352-3026(15)00045-9 · 2015
Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC–MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning
10.1016/j.jchromb.2017.04.025 · 2017
Population pharmacokinetics of fludarabine in children and adults during conditioning prior to allogeneic hematopoietic cell transplantation
10.1007/s40262-018-0715-9 · 2019
Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children
10.1016/j.bbmt.2012.10.010 · 2013
Prospective open-label phase II trial of individualized anti-thymocyte globulin for improved T-cell reconstitution after pediatric allogeneic hematopoietic cell transplantation: the parachute-study
10.1016/j.bbmt.2019.12.577 · 2020
Impact of conditioning regimen on outcomes for children with acute myeloid leukemia undergoing transplantation in first complete remission. An analysis on behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplanta
10.1016/j.bbmt.2016.11.022 · 2017
Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire
10.1038/bmt.2013.185 · 2014
Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens
10.1038/s41409-020-01201-w · 2021
Fifty years of melphalan use in hematopoietic stem cell transplantation
10.1016/j.bbmt.2012.08.011 · 2013
No additional external references are available.